The effect of telithromycin in acute exacerbations of asthma.

BACKGROUND We conducted a double-blind, randomized, placebo-controlled study to evaluate the efficacy of telithromycin in patients with acute exacerbations of asthma. METHODS A total of 278 adults with diagnosed asthma were enrolled within 24 hours after an acute exacerbation of asthma requiring short-term medical care. The patients were randomly assigned to receive 10 days of oral treatment with telithromycin (at a dose of 800 mg daily) or placebo in addition to usual care. Primary efficacy end points were a change from baseline over the treatment period in symptoms (as recorded by patients in a diary card) and in the peak expiratory flow in the morning at home. The presence of Chlamydophila pneumoniae or Mycoplasma pneumoniae was ascertained by serologic analysis, polymerase chain reaction, and culture. RESULTS Of the two prespecified primary outcomes, only asthma symptoms showed a significantly greater reduction among patients receiving telithromycin than among those receiving placebo. Mean (+/-SD) scores on a test of asthma symptoms (on a 7-point scale, with 0 denoting no symptoms and 6 denoting severe symptoms) were 3.0+/-1.4 at baseline and 1.7+/-1.1 at the end of treatment for the telithromycin group and 2.8+/-1.3 at baseline and 2.0+/-1.0 at the end of treatment for the placebo group. The mean decrease in symptom scores during the treatment period was 1.3 for telithromycin and 1.0 for placebo (mean difference, -0.3; 95 percent confidence interval, -0.5 to -0.1; P=0.004). There was no significant treatment effect on the other primary outcome measure, a change in morning peak expiratory flow. Nausea was more common among patients in the telithromycin group than in the placebo group (P=0.01). Although 61 percent of patients had evidence of infection with C. pneumoniae, M. pneumoniae, or both, there was no relationship between bacteriologic status and the response to asthma treatment. CONCLUSIONS This study provides evidence of the benefit of telithromycin in patients with acute exacerbations of asthma; the mechanisms of benefit remain unclear. (ClinicalTrials.gov number, NCT00273520.).

[1]  P. Banks,et al.  Brief Communication: Severe Hepatotoxicity of Telithromycin: Three Case Reports and Literature Review , 2006, Annals of Internal Medicine.

[2]  S. Johnston,et al.  Chlamydophila pneumoniae and Mycoplasma pneumoniae: a role in asthma pathogenesis? , 2005, American journal of respiratory and critical care medicine.

[3]  S. Johnston,et al.  Increased frequency of detection of Chlamydophila pneumoniae in asthma , 2004, European Respiratory Journal.

[4]  K. Chung,et al.  Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations , 2004, Thorax.

[5]  A. Tattersfield,et al.  Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial , 2004, The Lancet.

[6]  C. Carbon.  A Pooled Analysis of Telithromycin in the Treatment of Community-Acquired Respiratory Tract Infections in Adults , 2003, Infection.

[7]  J. Wernerman,et al.  Anaerobic bacteria commonly colonize the lower airways of intubated ICU patients. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  R. Krause,et al.  Laboratory diagnosis of Mycoplasma pneumoniae infection. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[9]  A. Rodloff,et al.  Drugs of the 21st century: telithromycin (HMR 3647)--the first ketolide. , 2003, The Journal of antimicrobial chemotherapy.

[10]  P. Gibson,et al.  Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma , 2002, European Respiratory Journal.

[11]  T. Slifer,et al.  Inhibition of Secretion of Interleukin-1α and Tumor Necrosis Factor Alpha by the Ketolide Antibiotic Telithromycin , 2002, Antimicrobial Agents and Chemotherapy.

[12]  Richard J Martin,et al.  Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma: effect of clarithromycin. , 2002, Chest.

[13]  M. Hammerschlag,et al.  Efficacy and safety of gemifloxacin in the treatment of community-acquired pneumonia: a randomized, double-blind comparison with trovafloxacin. , 2001, The Journal of antimicrobial chemotherapy.

[14]  M. Hammerschlag,et al.  Activity of telithromycin, a new ketolide antibacterial, against atypical and intracellular respiratory tract pathogens. , 2001, The Journal of antimicrobial chemotherapy.

[15]  R. Peeling,et al.  Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  C. Jenkins,et al.  Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae. , 2001, American journal of respiratory and critical care medicine.

[17]  B. Rowe,et al.  Antibiotics for acute asthma. , 2001, The Cochrane database of systematic reviews.

[18]  G. Daggard,et al.  Rapid-Cycle PCR Method To Detect Bordetella pertussis That Fulfills All Consensus Recommendations for Use of PCR in Diagnosis of Pertussis , 2000, Journal of Clinical Microbiology.

[19]  F. Kong,et al.  Rapid-Cycle PCR for Detection and Typing ofMycoplasma pneumoniae in Clinical Specimens , 2000, Journal of Clinical Microbiology.

[20]  Yasuaki Yamada,et al.  In Vitro Activity of Telithromycin (HMR3647), a New Ketolide, against Clinical Isolates of Mycoplasma pneumoniaein Japan , 2000, Antimicrobial Agents and Chemotherapy.

[21]  T. Reiss,et al.  A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. , 1998, The Journal of allergy and clinical immunology.

[22]  M. Hammerschlag,et al.  In Vitro Activity of a New Ketolide Antibiotic, HMR 3647, against Chlamydia pneumoniae , 1998, Antimicrobial Agents and Chemotherapy.

[23]  N. Santanello,et al.  Measurement characteristics of two asthma symptom diary scales for use in clinical trials. , 1997, The European respiratory journal.

[24]  C. Tong,et al.  Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. , 1993, Journal of clinical pathology.

[25]  E. Caul,et al.  The differentiation of Chlamydia species by antigen detection in sputum specimens from patients with community-acquired acute respiratory infections. , 1992, The Journal of infection.

[26]  P. Macfarlane,et al.  Clinical research group , 1989 .

[27]  A. Buist.  Standardization of spirometry. , 1987, The American review of respiratory disease.